Furthermore, ALKBH3 promoter CpG island hypermethylation and transcriptional silencing were found in Hodgkin lymphoma cells, which were identified as a potential prognostic biomarker associated with poor clinical outcomes in patients with Hodgkin lymphoma [58]. This evidence concerns the gene ALKBH3 and Hodgkins lymphoma.